Atezolizumab / Hyaluronidase Dosage
Medically reviewed by Drugs.com. Last updated on Oct 29, 2024.
Applies to the following strengths: tqjs 1875 mg-30,000 units/15 mL
Usual Adult Dose for:
- Non-Small Cell Lung Cancer
- Small Cell Lung Cancer
- Hepatocellular Carcinoma
- Melanoma - Metastatic
- Soft Tissue Sarcoma
Additional dosage information:
Usual Adult Dose for Non-Small Cell Lung Cancer
Atezolizumab 1875 mg-hyaluronidase 30,000 units subcutaneously every 3 weeks
Duration of therapy:
- As adjuvant monotherapy: Up to 1 year, unless there is disease recurrence or unacceptable toxicity
- For all other indications: Until disease progression or unacceptable toxicity
Comments:
- Administer this drug subcutaneously into the thigh over approximately 7 minutes.
- During combination therapy, this drug should be given before chemotherapy and bevacizumab when administered on the same day.
- When selecting patients for treatment, perform genomic tumor testing using an FDA-approved test.
- Consult the manufacturer product information of the therapeutic agents given in combination with this drug for dosing recommendations.
Use: Non-small cell lung cancer (NSCLC):
- As adjuvant monotherapy following resection and platinum-based chemotherapy, for the treatment of stage II to IIIA NSCLC with tumors that have programmed death-ligand 1 (PD-L1) expression on at least 1% of tumor cells
- As monotherapy, for the first-line treatment of metastatic NSCLC with tumors that have high PD-L1
- As monotherapy, for the treatment of metastatic NSCLC with disease progression during or following platinum-containing chemotherapy; patients with EGFR or ALK genomic tumor aberrations should
- In combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations
- In combination with paclitaxel protein-bound and carboplatin, for the first-line treatment of metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations
Usual Adult Dose for Small Cell Lung Cancer
Atezolizumab 1875 mg-hyaluronidase 30,000 units subcutaneously every 3 weeks, in combination with carboplatin and etoposide
Duration of therapy: Until disease progression or unacceptable toxicity
Comments:
- Administer this drug subcutaneously into the thigh over approximately 7 minutes.
- This drug should be given prior to chemotherapy when administered on the same day.
- Refer to the manufacturer product information of carboplatin and etoposide for dosing recommendations.
Use: In combination with carboplatin and etoposide, for the first-line treatment of extensive-stage small cell lung cancer
Usual Adult Dose for Hepatocellular Carcinoma
Atezolizumab 1875 mg-hyaluronidase 30,000 units subcutaneously every 3 weeks, in combination with bevacizumab 15 mg/kg IV every 3 weeks
Duration of therapy: Until disease progression or unacceptable toxicity
Comments:
- Administer this drug subcutaneously into the thigh over approximately 7 minutes.
- This drug should be given prior to bevacizumab when administered on the same day.
- Refer to the bevacizumab manufacturer product information before starting treatment.
Use: In combination with bevacizumab, for the treatment of unresectable or metastatic hepatocellular carcinoma not previously treated with systemic therapy
Usual Adult Dose for Melanoma - Metastatic
Atezolizumab 1875 mg-hyaluronidase 30,000 units subcutaneously every 3 weeks, in combination with cobimetinib and vemurafenib
Duration of therapy: Until disease progression or unacceptable toxicity
Comments:
- A 28-day treatment cycle of cobimetinib and vemurafenib is recommended prior to initiating therapy.
- Administer this drug subcutaneously into the thigh over approximately 7 minutes.
- Confirm the presence of a BRAF V600 tumor mutation using an FDA-approved test.
- Refer to the manufacturer product information of cobimetinib and vemurafenib before starting treatment.
Use: In combination with cobimetinib and vemurafenib, for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma
Usual Adult Dose for Soft Tissue Sarcoma
Atezolizumab 1875 mg-hyaluronidase 30,000 units subcutaneously every 3 weeks
Duration of therapy: Until disease progression or unacceptable toxicity
Comments:
- Administer this drug subcutaneously into the thigh over approximately 7 minutes.
Use: As monotherapy, for the treatment of unresectable or metastatic alveolar soft part sarcoma
Renal Dose Adjustments
IMMUNE-MEDIATED NEPHRITIS WITH RENAL DYSFUNCTION:
- Grades 2 or 3 increased blood creatinine: Withhold treatment. May resume therapy after complete or partial resolution (Grade 0 to 1) after corticosteroid taper. If within 12 weeks of initiating steroids either complete or partial resolution is not achieved or unable to reduce prednisone to 10 mg per day or less [or equivalent], then permanently discontinue.
- Grades 4 increased blood creatinine: Permanently discontinue therapy
Liver Dose Adjustments
IMMUNE-MEDIATED HEPATITIS:
Hepatitis With Tumor Involvement of Liver:
- If baseline AST or ALT is more than 1 to 3 times the upper limit of normal (3 x ULN) and increases greater than 5 to 10 x ULN, OR if baseline AST or ALT is more than 3 to 5 x ULN and increases greater than 8 to 10 x ULN: Withhold treatment. May resume therapy after complete or partial resolution (Grade 0 to 1) after corticosteroid taper. If within 12 weeks of initiating steroids either complete or partial resolution is not achieved or unable to reduce prednisone to 10 mg per day or less [or equivalent], then permanently discontinue therapy.
- If AST or ALT increases to more than 10 x ULN, OR total bilirubin increases to more than 3 x ULN: Permanently discontinue therapy
- If baseline AST and ALT are at the ULN or below: Withhold or permanently discontinue therapy based on recommendations for hepatitis with no liver involvement.
Hepatitis WithOUT Tumor Involvement of Liver:
- If AST or ALT increases more than 3 to 8 x ULN, OR total bilirubin increases more than 1.5 to 3 x ULN: Withhold treatment. Withhold treatment. May resume therapy after complete or partial resolution (Grade 0 to 1) after corticosteroid taper. If within 12 weeks of initiating steroids either complete or partial resolution is not achieved or unable to reduce prednisone to 10 mg per day or less [or equivalent], then permanently discontinue therapy.
- If AST or ALT increases more than 8 x ULN, OR total bilirubin increases more than 3 x ULN: Permanently discontinue therapy
Dose Adjustments
GENERAL CONSIDERATIONS:
- No dose reductions are recommended.
- In general, withhold therapy for severe (Grade 3) immune-mediated adverse reactions.
- Permanently discontinue treatment for:
- Life-threatening (Grade 4) immune-mediated adverse reactions
- Recurrent severe (Grade 3) immune-mediated adverse reactions requiring systemic immunosuppression
- Inability to reduce the daily corticosteroid dosage to 10 mg or less of prednisone (or equivalent) within 12 weeks of initiating corticosteroids
IMMUNE MEDIATED ADVERSE REACTIONS:
Colitis:
- Grade 2 or 3: Withhold treatment. May resume therapy after complete or partial resolution (Grade 0 to 1) after corticosteroid taper. If within 12 weeks of initiating steroids either complete or partial resolution is not achieved OR unable to reduce prednisone to 10 mg per day or less [or equivalent], then permanently discontinue therapy.
- Grade 4: Permanently discontinue therapy
Endocrinopathies:
- Grades 3 or 4: Withhold therapy until clinically stable, or permanently discontinue depending on severity
Exfoliative Dermatologic Conditions:
- Suspected Stevens-Johnson syndrome (SJS), drug reaction with eosinophilia and systemic symptoms (DRESS), or toxic epidermal necrolysis (TEN): Withhold treatment
- Confirmed SJS, DRESS, or TEN: Permanently discontinue therapy
Myocarditis or Pericarditis:
- Grades 2, 3, or 4: Permanently discontinue therapy
Neurological Toxicities:
- Grade 2: Withhold therapy. May resume therapy after complete or partial resolution (Grade 0 to 1) after corticosteroid taper. If within 12 weeks of initiating steroids either complete or partial resolution is not achieved OR unable to reduce prednisone to 10 mg per day or less [or equivalent], then permanently discontinue therapy.
- Grade 3 or 4: Permanently discontinue therapy
Pneumonitis:
- Grade 2: Withhold treatment. May resume therapy after complete or partial resolution (Grade 0 to 1) after corticosteroid taper. If within 12 weeks of initiating steroids either complete or partial resolution is not achieved OR unable to reduce prednisone to 10 mg per day or less [or equivalent], then permanently discontinue therapy.
- Grade 3 or 4: Permanently discontinue therapy
OTHER ADVERSE REACTIONS:
Infusion-Related Reactions:
- Grade 1 or 2: Pause or slow the rate of injection; consider premedication with antipyretic and antihistamines for subsequent doses.
- Grade 3 or 4: Permanently discontinue therapy
Precautions
CONTRAINDICATIONS:
- Known hypersensitivity to hyaluronidase or to any of the ingredients
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- For subcutaneous use in the thigh only; do NOT administer IV.
- This drug should be given by a health care professional.
- Inject subcutaneously into healthy skin over about 7 minutes, avoiding red, bruised, tender, or hard areas.
- Do not administer any remaining volume in the tubing to the patient.
- Alternate injection sites ensuring at least 2.5 cm between sites.
- When using concomitant subcutaneous drugs, administer those products at sites other than the thigh.
- This drug cannot be substituted for IV atezolizumab products due to different dosage recommendations.
- Patients currently on IV atezolizumab may switch to subcutaneous atezolizumab at the time of the next scheduled dose.
Pretreatment for patients with melanoma: Administer cobimetinib and vemurafenib prior to initiating therapy
- Days 1 to 21: Cobimetinib 60 mg orally once a day in combination with vemurafenib 960 mg orally twice a day.
- Days 22 to 28: Withhold cobimetinib, and administer vemurafenib 720 mg orally twice a day
Storage requirements:
- Refrigerate vials at 2C to 8C (36F to 46F) in original carton to protect from light; do not freeze or shake.
- Unpunctured vial: May be stored at room temperature [up to 25C (77F)] under ambient light for up to 4 hours prior to preparation for administration.
- Prepared syringe: If not for immediate use, do not attach a subcutaneous administration set. Store capped syringe at room temperature under ambient light for up to 8 hours OR refrigerated for up to 72 hours.
- Do not store prepared syringe attached to an already-primed subcutaneous administration set.
Reconstitution/preparation techniques:
- Consult the manufacturer product information prior to product preparation.
- Avoid potential errors by checking vial label to ensure formulation is for subcutaneous use.
- Allow refrigerated vials to come to room temperature before preparation; do not shake or dilute.
- The priming volume of the subcutaneous administration set should NOT exceed 0.5 mL.
- Immediately administer syringe with primed subcutaneous administration set to avoid needle clogging.
Compatibility:
- This drug is compatible with stainless steel transfer and injection needles, and polypropylene, polycarbonate, polyvinyl chloride, and polyurethane syringe material and subcutaneous administration sets.
General:
- Information on FDA-approved tests for the determination of PD-L1 expression in NSCLC or for detection of BRAF V600 mutations in melanoma is available at: http://www.fda.gov/CompanionDiagnostics.
Monitoring:
- Immunologic: For signs/symptoms of immune-mediated adverse reactions (during therapy); monitor liver
- Local: For signs/symptoms of infusion-related reactions (during therapy)
- Metabolic: For hyperglycemia or other signs/symptoms of diabetes (during therapy)
- Other: For complications in patients who received allogenic hematopoietic stem cell transplant (HSCT) before or after treatment with this drug (during therapy)
Patient advice:
- Read the US FDA-approved patient labeling (Medication Guide).
- Understand the risk of immune-mediated adverse reactions associated with use of this drug.
- Contact your health care provider immediately if signs/symptoms of immune-mediate reactions occur.
- Notify your health care provider for signs or symptoms of infusion-related adverse events.
- Recognize the risk associated with therapy if this drug is used prior to or after an allogeneic HSCT.
- Patients of childbearing potential: Understand this drug may cause fetal harm. Use effective contraception during therapy and for 5 months after the last dose.
- Breastfeeding is not recommended during therapy and for 5 months after the last dose.
More about atezolizumab / hyaluronidase
- Check interactions
- Compare alternatives
- Side effects
- During pregnancy
- Drug class: anti-PD-1 and PD-L1 monoclonal antibodies (immune checkpoint inhibitors)
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
See also:
Opdivo Qvantig
Opdivo Qvantig is used to treat adults with melanoma, non-small cell lung cancer, renal cell ...
Rybrevant
Rybrevant is used to treat certain types of non-small cell lung cancer (NSCLC) in adults. It is ...
Enhertu
Enhertu is a treatment for breast cancer, stomach cancer, and non-small cell lung cancer with HER2 ...
Opdivo
Opdivo is used to treat many cancers, such as melanoma, non-small cell lung cancer, malignant ...
Keytruda
Keytruda is used to treat multiple types of cancer such as melanoma, non-small cell lung cancer ...
Avastin
Avastin is used to brain tumors and cancers of the kidney, colon, rectum, or lung. Learn about side ...
Tagrisso
Tagrisso (osimertinib) may be used to treat adults with non-small cell lung cancer (NSCLC) whose ...
Docetaxel
Docetaxel systemic is used for breast cancer, breast cancer, metastatic, gastric cancer, head and ...
Nivolumab
Nivolumab (brand name Opdivo) is an immunotherapy treatment that treats many cancers, such as ...
Paclitaxel
Paclitaxel systemic is used for breast cancer, breast cancer, adjuvant, breast cancer, metastatic ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.